Cargando…
Surgical treatment on infective endocarditis: impact of diabetes on mortality
BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients suffering from infective endocarditis (IE). The aim of the study was to evaluate the impact of type 2 DM on the early-, intermediate- and long-term mortality of patients who underwent surgical treatment of endocardit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248198/ https://www.ncbi.nlm.nih.gov/pubmed/35773698 http://dx.doi.org/10.1186/s12933-022-01557-x |
_version_ | 1784739320193613824 |
---|---|
author | Kogan, Alexander Wieder-Finesod, Anat Frogel, Jonathan Peled-Potashnik, Yael Ram, Eilon Raanani, Ehud Sternik, Leonid |
author_facet | Kogan, Alexander Wieder-Finesod, Anat Frogel, Jonathan Peled-Potashnik, Yael Ram, Eilon Raanani, Ehud Sternik, Leonid |
author_sort | Kogan, Alexander |
collection | PubMed |
description | BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients suffering from infective endocarditis (IE). The aim of the study was to evaluate the impact of type 2 DM on the early-, intermediate- and long-term mortality of patients who underwent surgical treatment of endocarditis. METHODS: We performed an observational cohort study in the large tertiary center in Israel during 14 years. All data of patients who underwent surgical treatment of endocarditis, performed between 2006 and 2020 were extracted from the departmental database. Patients were divided into two groups: Group I (non-diabetic patients), and Group II (diabetic patients). RESULTS: The study population includes 420 patients. Group I (non-diabetic patients), comprise 326 patients, and Group II (diabetic patients), comprise 94 patients. Mean follow-up duration was 39.3 ± 28.1 months. Short-term, 30-day and in-hospital mortality, also intermediate-term mortality (1- and 3-year) was higher in the DM group compared with the non-DM group, but did not reach statistical significance: 11.7% vs. 7.7%. (p = 0.215); 12.8% vs. 8.3% (p = 0.285); 20.2% vs. 13.2% (p = 0.1) and 23.4% vs. 15.6% (p = 0.09) respectively. Long-term, 5-year mortality was significantly higher in the DM group, compared to the non-DM group: 30.9% vs. 16.6% (p = 0.003). Furthermore, predictors for long-term mortality included diabetes (CI 1.056–2.785, p = 0.029), as demonstrated by regression analysis. CONCLUSIONS: Diabetic patients have trend to increasing mortality at the short- and intermediate period post-surgery for IE, but this is not statistically significant. Survival of diabetic patients deteriorates after more than three years follow surgery. Diabetes is an independent predictor for long-term, 5-year mortality after surgical treatment of endocarditis, regardless of the patients age and comorbidities. Trial registration Ethical Committee of Sheba Medical Centre, Israel on 02.12. 2014, Protocol 4257 |
format | Online Article Text |
id | pubmed-9248198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92481982022-07-02 Surgical treatment on infective endocarditis: impact of diabetes on mortality Kogan, Alexander Wieder-Finesod, Anat Frogel, Jonathan Peled-Potashnik, Yael Ram, Eilon Raanani, Ehud Sternik, Leonid Cardiovasc Diabetol Research BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients suffering from infective endocarditis (IE). The aim of the study was to evaluate the impact of type 2 DM on the early-, intermediate- and long-term mortality of patients who underwent surgical treatment of endocarditis. METHODS: We performed an observational cohort study in the large tertiary center in Israel during 14 years. All data of patients who underwent surgical treatment of endocarditis, performed between 2006 and 2020 were extracted from the departmental database. Patients were divided into two groups: Group I (non-diabetic patients), and Group II (diabetic patients). RESULTS: The study population includes 420 patients. Group I (non-diabetic patients), comprise 326 patients, and Group II (diabetic patients), comprise 94 patients. Mean follow-up duration was 39.3 ± 28.1 months. Short-term, 30-day and in-hospital mortality, also intermediate-term mortality (1- and 3-year) was higher in the DM group compared with the non-DM group, but did not reach statistical significance: 11.7% vs. 7.7%. (p = 0.215); 12.8% vs. 8.3% (p = 0.285); 20.2% vs. 13.2% (p = 0.1) and 23.4% vs. 15.6% (p = 0.09) respectively. Long-term, 5-year mortality was significantly higher in the DM group, compared to the non-DM group: 30.9% vs. 16.6% (p = 0.003). Furthermore, predictors for long-term mortality included diabetes (CI 1.056–2.785, p = 0.029), as demonstrated by regression analysis. CONCLUSIONS: Diabetic patients have trend to increasing mortality at the short- and intermediate period post-surgery for IE, but this is not statistically significant. Survival of diabetic patients deteriorates after more than three years follow surgery. Diabetes is an independent predictor for long-term, 5-year mortality after surgical treatment of endocarditis, regardless of the patients age and comorbidities. Trial registration Ethical Committee of Sheba Medical Centre, Israel on 02.12. 2014, Protocol 4257 BioMed Central 2022-06-30 /pmc/articles/PMC9248198/ /pubmed/35773698 http://dx.doi.org/10.1186/s12933-022-01557-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kogan, Alexander Wieder-Finesod, Anat Frogel, Jonathan Peled-Potashnik, Yael Ram, Eilon Raanani, Ehud Sternik, Leonid Surgical treatment on infective endocarditis: impact of diabetes on mortality |
title | Surgical treatment on infective endocarditis: impact of diabetes on mortality |
title_full | Surgical treatment on infective endocarditis: impact of diabetes on mortality |
title_fullStr | Surgical treatment on infective endocarditis: impact of diabetes on mortality |
title_full_unstemmed | Surgical treatment on infective endocarditis: impact of diabetes on mortality |
title_short | Surgical treatment on infective endocarditis: impact of diabetes on mortality |
title_sort | surgical treatment on infective endocarditis: impact of diabetes on mortality |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248198/ https://www.ncbi.nlm.nih.gov/pubmed/35773698 http://dx.doi.org/10.1186/s12933-022-01557-x |
work_keys_str_mv | AT koganalexander surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality AT wiederfinesodanat surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality AT frogeljonathan surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality AT peledpotashnikyael surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality AT rameilon surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality AT raananiehud surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality AT sternikleonid surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality |